- Formyl acetamide azole derivative and use thereof
-
The invention belongs to the field of drug synthesis, and relates to a novel formyl acetamide azole derivative and pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, preparation methods, and a drug composition containing the compound. The formyl acetamide azole derivative disclosed by the invention has a relatively strong antifungal effect. A formyl acetamide azole compound asshown in a general formula I provided by the invention is shown in the specification.
- -
-
Paragraph 0053-0055
(2020/04/17)
-
- BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2
-
The present invention directs to a compound represented by formula (I).
- -
-
Page/Page column 419; 427; 428
(2017/08/01)
-
- FUSED MORPHLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present invention relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
Paragraph 0265
(2015/05/19)
-
- FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
- -
-
Paragraph 0175
(2015/10/05)
-
- PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE
-
The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising th
- -
-
Page/Page column 60
(2012/06/15)
-
- Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand
-
A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for P4 ligands in combination with a neutral biaryl P1 ligand were investigated with the 2-carboxyindole scaffold. A diverse set of P4 substituents was identified, which, in conjunction with a biaryl P1 ligand, gave highly potent factor Xa inhibitors, which were also selective versus other proteases and efficacious in various antithrombotic secondary assays.
- Nazare, Marc,Essrich, Melanie,Will, David W.,Matter, Hans,Ritter, Kurt,Urmann, Matthias,Bauer, Armin,Schreuder, Herman,Czech, Joerg,Lorenz, Martin,Laux, Volker,Wehner, Volkmar
-
p. 4197 - 4201
(2007/10/03)
-
- NEW COMPOUNDS
-
The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.
- -
-
Page/Page column 33; 34
(2008/06/13)
-
- New indole derivatives as factor Xa inhibitors
-
The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.
- -
-
Page/Page column 76
(2008/06/13)
-